Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial Source: Eur Respir J, 55 (5) 1902370; 10.1183/13993003.02370-2019 Year: 2020
Three drug regimen in SCLC-ED patients: a phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022
A phase II study with gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma (MM): preliminary report Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial Source: Eur Respir J 2010; 36: 1362-1369 Year: 2010
Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021
Paclitaxel/carboplatin vs paclitaxel/carboplatin/etoposide as first line treatment in SCLC. A phase III randomized trial Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018
Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019
Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005